BM L12
Alternative Names: BM-L12Latest Information Update: 02 Sep 2024
Price :
$50 *
At a glance
- Originator Shenzhen Beimei Pharmaceutical
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Otitis externa; Otitis media
Most Recent Events
- 05 Aug 2024 Preclinical trials in Otitis externa in China (Otic), prior to August 2024 (Shenzhen Beimei Pharmaceutical pipeline, August 2024)
- 05 Aug 2024 Preclinical trials in Otitis media in China (Otic), prior to August 2024 (Shenzhen Beimei Pharmaceutical pipeline, August 2024)
- 05 Aug 2024 Shenzhen Beimei Pharmaceutical announces intention to file an IND application for acute otitis media and acute otitis externa (Shenzhen Beimei Pharmaceutical pipeline, August 2024)